Federal Register of Legislation - Australian Government

Primary content

PB 60 of 2019 Other as made
This instrument amends Schedule 1 of the National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015) to add, delete and alter listed pharmaceutical items and associated periods and circumstances.
Administered by: Health
Registered 29 Jul 2019
Tabling HistoryDate
Tabled HR30-Jul-2019
Tabled Senate31-Jul-2019
To be repealed 13 Nov 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 60 of 2019

 

National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2019 (No. 7)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated  26 July 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


 

___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2019 (No. 7).

(2)          This Instrument may also be cited as PB 60 of 2019.

2          Commencement

This Instrument commences on 1 August 2019.

3          Amendment of National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015).

 


Schedule 1       Amendments

[1]        Schedule 1, entry for Calcium

omit:

 

Tablet, chewable, 500 mg (as carbonate)

20

240

1

 

[2]        Schedule 1, after entry for Flutamide

insert:

Fluticasone furoate

Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses

20

1

5

 

 

Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses

20

1

5

 

[3]        Schedule 1, after entry for Testosterone in the form Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2

insert:

 

Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses

20

1

5

 

[4]        Schedule 1, after entry for Tiotropium with olodaterol

insert:

Tocilizumab

Injection 162 mg in 0.9 mL single use pre-filled pen

20

4

5

 

 

 

20

4

6

 

 

Injection 162 mg in 0.9 mL single use pre-filled syringe

20

4

5

 

 

 

20

4

6